1 | least | 26,899 |
2 | home/chez | 11 |
3 | lark | 7 |
4 | fitbit | 6 |
5 | bhumibol | 5 |
6 | lease | 5 |
7 | www.isrctn.com | 4 |
8 | treatments.only | 3 |
9 | 1250°c | 2 |
10 | 60x | 2 |
11 | baseline/after | 2 |
12 | bilogora | 2 |
13 | clatterbridge | 2 |
14 | cmdhs | 2 |
15 | heidelberger | 2 |
16 | intervention.only | 2 |
17 | rr1/rr2=1 | 2 |
18 | tamin | 2 |
19 | www.clinicaltrialsregister.eu | 2 |
20 | yüksek | 2 |
21 | -524 | 1 |
22 | -80c | 1 |
23 | 0.5mcg/kg/hr | 1 |
24 | 0.9mg/kg | 1 |
25 | 10,750 | 1 |
26 | 10:00h | 1 |
27 | 110-140°c | 1 |
28 | 1200μa | 1 |
29 | 1390+/-235 | 1 |
30 | 1mpa/s | 1 |
31 | 27+0- | 1 |
32 | 2and | 1 |
33 | 30.6.05 | 1 |
34 | 300ml/hr | 1 |
35 | 335mg/day | 1 |
36 | 375μm | 1 |
37 | 3nmol | 1 |
38 | 4-5°c | 1 |
39 | 4-and | 1 |
40 | 40°c.we | 1 |
41 | 44-47°c | 1 |
42 | 479nm | 1 |
43 | 6dpf | 1 |
44 | 919.88 | 1 |
45 | ali- | 1 |
46 | ambient-115°c | 1 |
47 | anti-ferro-magnetic | 1 |
48 | atp-ases | 1 |
49 | baseline.sti | 1 |
50 | beta-frequency | 1 |
51 | bikur | 1 |
52 | biomedcentral.com | 1 |
53 | birth.of | 1 |
54 | c-3position | 1 |
55 | c.293-13c | 1 |
56 | cbct-guided | 1 |
57 | chlorhexidine.only | 1 |
58 | clincialtrails.gov | 1 |
59 | controlled-trials.com/isrctn/ | 1 |
60 | cost-effective- | 1 |
61 | day+28 | 1 |
62 | diakinesis | 1 |
63 | folk-focused | 1 |
64 | follow-up.at | 1 |
65 | head-points | 1 |
66 | hermanos | 1 |
67 | hillerød | 1 |
68 | inlier | 1 |
69 | inrca | 1 |
70 | intra-individiual | 1 |
71 | jubbah | 1 |
72 | k40-w50 | 1 |
73 | kariobangi | 1 |
74 | kohnan | 1 |
75 | least- | 1 |
76 | low-progression | 1 |
77 | matab | 1 |
78 | max-planck-institut | 1 |
79 | menlung | 1 |
80 | misimpur | 1 |
81 | murtala | 1 |
82 | night-is | 1 |
83 | nuestra | 1 |
84 | overprocessed | 1 |
85 | pound465,862,416 | 1 |
86 | q≤ | 1 |
87 | randomisation.in | 1 |
88 | randomisation.twenty | 1 |
89 | recruitment.once | 1 |
90 | sarwar | 1 |
91 | ser-67 | 1 |
92 | ser63 | 1 |
93 | softest | 1 |
94 | sparsest | 1 |
95 | t2-t | 1 |
96 | t6-t9 | 1 |
97 | t9/t10 | 1 |
98 | t=180min | 1 |
99 | tuch | 1 |
100 | tweaking | 1 |
101 | uk.2 | 1 |
102 | uncertain.table | 1 |
103 | week4 | 1 |
104 | www.clinicaltrails.gov | 1 |
105 | www.controlled-trials.com/isrctn/ | 1 |
106 | www.isrctin.org | 1 |
107 | www/controlled-trials.com/mrct/ | 1 |
108 | x=0.02 | 1 |
109 | younger-looking | 1 |
110 | ≤6h | 1 |
1 | -524 | 1 |
2 | -80c | 1 |
3 | 0.5mcg/kg/hr | 1 |
4 | 0.9mg/kg | 1 |
5 | 10,750 | 1 |
6 | 10:00h | 1 |
7 | 110-140°c | 1 |
8 | 1200μa | 1 |
9 | 1250°c | 2 |
10 | 1390+/-235 | 1 |
11 | 1mpa/s | 1 |
12 | 27+0- | 1 |
13 | 2and | 1 |
14 | 30.6.05 | 1 |
15 | 300ml/hr | 1 |
16 | 335mg/day | 1 |
17 | 375μm | 1 |
18 | 3nmol | 1 |
19 | 4-5°c | 1 |
20 | 4-and | 1 |
21 | 40°c.we | 1 |
22 | 44-47°c | 1 |
23 | 479nm | 1 |
24 | 60x | 2 |
25 | 6dpf | 1 |
26 | 919.88 | 1 |
27 | ali- | 1 |
28 | ambient-115°c | 1 |
29 | anti-ferro-magnetic | 1 |
30 | atp-ases | 1 |
31 | baseline.sti | 1 |
32 | baseline/after | 2 |
33 | beta-frequency | 1 |
34 | bhumibol | 5 |
35 | bikur | 1 |
36 | bilogora | 2 |
37 | biomedcentral.com | 1 |
38 | birth.of | 1 |
39 | c-3position | 1 |
40 | c.293-13c | 1 |
41 | cbct-guided | 1 |
42 | chlorhexidine.only | 1 |
43 | clatterbridge | 2 |
44 | clincialtrails.gov | 1 |
45 | cmdhs | 2 |
46 | controlled-trials.com/isrctn/ | 1 |
47 | cost-effective- | 1 |
48 | day+28 | 1 |
49 | diakinesis | 1 |
50 | fitbit | 6 |
51 | folk-focused | 1 |
52 | follow-up.at | 1 |
53 | head-points | 1 |
54 | heidelberger | 2 |
55 | hermanos | 1 |
56 | hillerød | 1 |
57 | home/chez | 11 |
58 | inlier | 1 |
59 | inrca | 1 |
60 | intervention.only | 2 |
61 | intra-individiual | 1 |
62 | jubbah | 1 |
63 | k40-w50 | 1 |
64 | kariobangi | 1 |
65 | kohnan | 1 |
66 | lark | 7 |
67 | lease | 5 |
68 | least | 26,899 |
69 | least- | 1 |
70 | low-progression | 1 |
71 | matab | 1 |
72 | max-planck-institut | 1 |
73 | menlung | 1 |
74 | misimpur | 1 |
75 | murtala | 1 |
76 | night-is | 1 |
77 | nuestra | 1 |
78 | overprocessed | 1 |
79 | pound465,862,416 | 1 |
80 | q≤ | 1 |
81 | randomisation.in | 1 |
82 | randomisation.twenty | 1 |
83 | recruitment.once | 1 |
84 | rr1/rr2=1 | 2 |
85 | sarwar | 1 |
86 | ser-67 | 1 |
87 | ser63 | 1 |
88 | softest | 1 |
89 | sparsest | 1 |
90 | t2-t | 1 |
91 | t6-t9 | 1 |
92 | t9/t10 | 1 |
93 | t=180min | 1 |
94 | tamin | 2 |
95 | treatments.only | 3 |
96 | tuch | 1 |
97 | tweaking | 1 |
98 | uk.2 | 1 |
99 | uncertain.table | 1 |
100 | week4 | 1 |
101 | www.clinicaltrails.gov | 1 |
102 | www.clinicaltrialsregister.eu | 2 |
103 | www.controlled-trials.com/isrctn/ | 1 |
104 | www.isrctin.org | 1 |
105 | www.isrctn.com | 4 |
106 | www/controlled-trials.com/mrct/ | 1 |
107 | x=0.02 | 1 |
108 | younger-looking | 1 |
109 | yüksek | 2 |
110 | ≤6h | 1 |
1 | 27+0- | 1 |
2 | cost-effective- | 1 |
3 | ali- | 1 |
4 | least- | 1 |
5 | controlled-trials.com/isrctn/ | 1 |
6 | www.controlled-trials.com/isrctn/ | 1 |
7 | www/controlled-trials.com/mrct/ | 1 |
8 | t9/t10 | 1 |
9 | 10,750 | 1 |
10 | k40-w50 | 1 |
11 | rr1/rr2=1 | 2 |
12 | uk.2 | 1 |
13 | x=0.02 | 1 |
14 | ser63 | 1 |
15 | -524 | 1 |
16 | week4 | 1 |
17 | 30.6.05 | 1 |
18 | 1390+/-235 | 1 |
19 | pound465,862,416 | 1 |
20 | ser-67 | 1 |
21 | day+28 | 1 |
22 | 919.88 | 1 |
23 | t6-t9 | 1 |
24 | inrca | 1 |
25 | murtala | 1 |
26 | bilogora | 2 |
27 | nuestra | 1 |
28 | 1200μa | 1 |
29 | matab | 1 |
30 | -80c | 1 |
31 | c.293-13c | 1 |
32 | anti-ferro-magnetic | 1 |
33 | 110-140°c | 1 |
34 | 1250°c | 2 |
35 | 4-5°c | 1 |
36 | ambient-115°c | 1 |
37 | 44-47°c | 1 |
38 | cbct-guided | 1 |
39 | overprocessed | 1 |
40 | folk-focused | 1 |
41 | 4-and | 1 |
42 | 2and | 1 |
43 | hillerød | 1 |
44 | recruitment.once | 1 |
45 | clatterbridge | 2 |
46 | uncertain.table | 1 |
47 | lease | 5 |
48 | 40°c.we | 1 |
49 | birth.of | 1 |
50 | 6dpf | 1 |
51 | 0.9mg/kg | 1 |
52 | tweaking | 1 |
53 | younger-looking | 1 |
54 | menlung | 1 |
55 | www.isrctin.org | 1 |
56 | 10:00h | 1 |
57 | ≤6h | 1 |
58 | jubbah | 1 |
59 | tuch | 1 |
60 | kariobangi | 1 |
61 | baseline.sti | 1 |
62 | yüksek | 2 |
63 | lark | 7 |
64 | intra-individiual | 1 |
65 | bhumibol | 5 |
66 | 3nmol | 1 |
67 | 479nm | 1 |
68 | biomedcentral.com | 1 |
69 | www.isrctn.com | 4 |
70 | 375μm | 1 |
71 | kohnan | 1 |
72 | randomisation.in | 1 |
73 | t=180min | 1 |
74 | tamin | 2 |
75 | low-progression | 1 |
76 | c-3position | 1 |
77 | sarwar | 1 |
78 | heidelberger | 2 |
79 | inlier | 1 |
80 | baseline/after | 2 |
81 | 0.5mcg/kg/hr | 1 |
82 | 300ml/hr | 1 |
83 | bikur | 1 |
84 | misimpur | 1 |
85 | 1mpa/s | 1 |
86 | atp-ases | 1 |
87 | cmdhs | 2 |
88 | night-is | 1 |
89 | diakinesis | 1 |
90 | hermanos | 1 |
91 | head-points | 1 |
92 | t2-t | 1 |
93 | follow-up.at | 1 |
94 | fitbit | 6 |
95 | least | 26,899 |
96 | sparsest | 1 |
97 | softest | 1 |
98 | max-planck-institut | 1 |
99 | www.clinicaltrialsregister.eu | 2 |
100 | www.clinicaltrails.gov | 1 |
101 | clincialtrails.gov | 1 |
102 | 60x | 2 |
103 | 335mg/day | 1 |
104 | beta-frequency | 1 |
105 | chlorhexidine.only | 1 |
106 | intervention.only | 2 |
107 | treatments.only | 3 |
108 | randomisation.twenty | 1 |
109 | home/chez | 11 |
110 | q≤ | 1 |